BRAFi used are as follows: PLX4032 (vemurafenib; MedChemExpress, #HY-12057), LGX818 (encorafenib; MedChemExpress, #HY-15605), GSK2118436A (dabrafenib; Selleckchem, #S2807), PLX8394 (MedChemExpress, #HY-18972), AZ628 (Selleckchem, #S2746), GDC0879 (Selleckchem, #S1104), LY3009120 (Selleckchem, #S7842), and TAK632 (Selleckchem, #S7291). MEKi used are as follows: AZD6244 (selumetinib; Selleckchem, #S1008), BAY86-9766 (refametinib; MedChemExpress, #HY-102156), and benzyl-coelenterazine (NanoLight, #301).

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.